Entero Healthcare Solutions544122Quarterly results
Q2 results with unmodified limited review, plus 49,712 fresh ESOPs
Board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 20,870.75 | 15,709.48 | +32.9% | 19,404.95 | +7.6% |
| Total income | 20,910.67 | 15,757.39 | +32.7% | 19,435.02 | +7.6% |
| Profit before tax | 783.87 | 446.25 | +75.7% | 671.20 | +16.8% |
| Profit after tax | 607.42 | 366.00 | +66% | 520.51 | +16.7% |
| Total comprehensive income | 628.03 | 361.85 | +73.6% | 519.21 | +21% |
| Basic EPS | 10.47 | 7.26 | +44.2% | 8.77 | +19.4% |
- Total income
- Latest 20,910.67; Year ago 15,757.39 (+32.7%); Prev qtr 19,435.02 (+7.6%)
- Profit after tax
- Latest 607.42; Year ago 366.00 (+66%); Prev qtr 520.51 (+16.7%)
- Period
- 30 September 2026 (Unaudited)
Also decided at the meeting
- Board noted the grant of fresh 49,712 Employee Stock Options under the existing Entero Employee Stock Option Plan 2023, as approved by the Nomination & Remuneration Committee.
Auditor's review
Conclusion: Unmodified
Notes to the results
- Subsidiaries acquired during FY ended 31 March 2026 are accounted under Ind AS 103 on provisional basis; figures for the quarter and half year are not comparable with comparative periods.
- R S M Pharma Private Limited subscribed to 100% equity of Qurovia Lifesciences Private Limited on 25 July 2026, making it a step-down subsidiary.
- Company allotted 12,135 equity shares of Rs.10 each at a premium of Rs. 794 per share aggregating to Rs. 9.76 million on exercise of employee stock options.
- Subsequent to period end, Sai Pharma Distributors Private Limited agreed on 12 October 2026 to acquire 100% business undertaking of Vishal Surgicals and Vishal Surgicals & Medicals on slump sale basis.
Board meeting outcome
Entero Healthcare Solutions Ltd disclosed the outcome of its board meeting held on November 4, 2026. The board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and noted a fresh grant of employee stock options. The company operates in a single business segment, trading of pharmaceutical and surgical products.
Auditor's review conclusion
- The statutory auditors, M S K A & Associates LLP, issued Limited Review Reports with an unmodified opinion on both the standalone and consolidated results.
- In simple terms, the review did not bring anything to the auditors' attention suggesting the statements were misstated or did not contain the disclosures required.
- These are reviewed but unaudited interim results, not a full statutory audit.
Consolidated results (figures in Rs. million, as printed)
- Revenue from operations: 20,870.75 for the quarter ended September 30, 2026, against 15,709.48 for the quarter ended September 30, 2025.
- Profit for the period: 607.42, against 366.00 in the year-earlier quarter.
- The consolidated statement includes the company together with its subsidiaries.
Standalone results (figures in Rs. million, as printed)
- Revenue from operations: 1,145.71 for the quarter ended September 30, 2026.
- Profit for the period: 191.44 for the same quarter.
- Standalone numbers reflect the parent entity alone, so they are much smaller than the consolidated figures.
Employee stock options
- The board noted the grant of 49,712 fresh Employee Stock Options under the "Entero Employee Stock Option Plan 2023", after the Nomination & Remuneration Committee approved it at its meeting earlier the same day.
- During the quarter, 12,135 equity shares were allotted following exercise of employee stock options.
- Options convert into shares when exercised, so the share count can rise over time; existing shareholders often track this as dilution.
Trading window
- The company said the trading window for dealing in its securities will open after the prescribed gap following disclosure of the financial results, as per its internal code for sharing unpublished price-sensitive information.
- A closed window restricts insiders from trading; its reopening is a routine sequencing item around results.
What a reader can take away
- Two things came out of the meeting: the reviewed quarterly numbers and a fresh ESOP grant.
- The revenue and profit lines above are the headline items to compare across periods; the auditor's conclusion was clean, with an unmodified opinion.
₹20,870.75 MnConsolidated Revenue from operations, (Rs. in Million
Total income, quarter19,435.02 (Rs. in Million)
Total comprehensive income, latest quarter628.03 (Rs. in Million)
Total comprehensive income, quarter519.21 (Rs. in Million)
Total comprehensive income, year-ago quarter361.85 (Rs. in Million)
Also from Entero Healthcare Solutions
Wholly owned subsidiary's customer defaults on INR 11.87 crore dues; entire amount provisioned
4 Nov 2026
Entero Healthcare Q2FY27 revenue up 33% to Rs. 2,087.1 crore, PAT up 66%; targets Rs. 1,000 crore MedTech revenue in FY27
4 Nov 2026
Board approves Q2/H1 FY27 results with unmodified limited review; notes grant of 49,712 fresh ESOPs
4 Nov 2026
More numbers
- Standalone Revenue from operations, quarter ended 30 Sep 2026 (Rs. in Million)1,145.71
- Standalone Profit for the period, quarter ended 30 Sep 2026 (Rs. in Million)191.44
- Fresh Employee Stock Options granted under ESOP Plan 202349,712
- Equity shares allotted on exercise of employee stock options12,135
- Total income, latest quarter20,910.67 (Rs. in Million)
- Total income, year-ago quarter15,757.39 (Rs. in Million)
- Total income, previous quarter19,435.02 (Rs. in Million)
- Total comprehensive income, latest quarter628.03 (Rs. in Million)
- Total comprehensive income, year-ago quarter361.85 (Rs. in Million)
- Total comprehensive income, previous quarter519.21 (Rs. in Million)
- Profit after tax, latest quarter607.42 (Rs. in Million)
- Profit after tax, year-ago quarter366.00 (Rs. in Million)
- Profit after tax, previous quarter520.51 (Rs. in Million)
- Revenue from operations, latest quarter20,870.75 (Rs. in Million)
- Revenue from operations, year-ago quarter15,709.48 (Rs. in Million)
- Revenue from operations, previous quarter19,404.95 (Rs. in Million)
- Profit before tax, latest quarter783.87 (Rs. in Million)
- Profit before tax, year-ago quarter446.25 (Rs. in Million)
- Profit before tax, previous quarter671.20 (Rs. in Million)
Source: BSE · 4 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.